Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 1
1954 4
1955 4
1956 1
1957 1
1958 6
1959 1
1960 5
1961 1
1962 2
1963 4
1964 1
1965 2
1966 2
1967 7
1968 8
1969 12
1970 8
1971 3
1972 2
1973 6
1974 3
1975 7
1976 3
1977 1
1978 9
1979 5
1980 1
1982 1
1983 2
1984 1
1985 3
1987 4
1988 5
1989 8
1990 6
1991 3
1992 1
1993 3
1994 4
1995 2
1996 3
1997 4
1998 3
1999 7
2000 5
2001 16
2002 19
2003 25
2004 23
2005 24
2006 35
2007 21
2008 26
2009 26
2010 26
2011 25
2012 20
2013 23
2014 30
2015 49
2016 36
2017 46
2018 54
2019 69
2020 74
2021 61
2022 65
2023 59
2024 73
2025 73
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,045 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Janjigian YY, et al. Among authors: omori t. N Engl J Med. 2025 Jul 17;393(3):217-230. doi: 10.1056/NEJMoa2503701. Epub 2025 Jun 1. N Engl J Med. 2025. PMID: 40454643 Clinical Trial.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: omori t. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K; Japanese Study Group of Kidney Disease in Children. Iijima K, et al. Among authors: omori t. J Am Soc Nephrol. 2022 Feb;33(2):401-419. doi: 10.1681/ASN.2021050643. Epub 2021 Dec 8. J Am Soc Nephrol. 2022. PMID: 34880074 Free PMC article. Clinical Trial.
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Kang YK, et al. Among authors: omori t. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18. Lancet Gastroenterol Hepatol. 2024. PMID: 38906161 Clinical Trial.
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, Kadowaki S, Tsuji K, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Chung IJ, Sym SJ, Chen LT, Chen JS, Bai LY, Nakada T, Hagihara S, Makino R, Nishiyama E, Kang YK. Boku N, et al. Among authors: omori t. Gastric Cancer. 2024 Nov;27(6):1287-1301. doi: 10.1007/s10120-024-01535-0. Epub 2024 Aug 20. Gastric Cancer. 2024. PMID: 39162872 Free PMC article. Clinical Trial.
Endoscopic imaging in inflammatory bowel disease.
Nagasaka M, Nakagawa Y, Kamano T, Omori T, Nakaoka K, Funasaka K, Miyahara R, Hashimoto S, Shibata T, Hirooka Y. Nagasaka M, et al. Among authors: omori t. J Med Ultrason (2001). 2023 Jul;50(3):321-326. doi: 10.1007/s10396-022-01250-2. Epub 2022 Aug 29. J Med Ultrason (2001). 2023. PMID: 36036332 Review.
Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer.
Yanagimoto Y, Yamamoto K, Hara K, Masuike Y, Ushimaru Y, Kitamura M, Honma K, Matsuura N, Sugase T, Kanemura T, Mori R, Kitakaze M, Amisaki M, Kubo M, Mukai Y, Komatsu H, Sueda T, Kagawa Y, Nishimura J, Wada H, Goto K, Yasui M, Omori T, Miyata H. Yanagimoto Y, et al. Among authors: omori t. Jpn J Clin Oncol. 2025 Jul 6;55(7):825-831. doi: 10.1093/jjco/hyaf055. Jpn J Clin Oncol. 2025. PMID: 40194315
1,045 results